 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ALA-101 / Arovella Therap
Allogeneic CD19-directed CAR-iNKT cells and their phenotypic subsets for the treatment of CD19+ hematological malignancies (Section 2) - Mar 5, 2024 - Abstract #AACR2024AACR_4206;
In summary, inclusion of both CD4+ and CD4- iNKT cells is critical for the functionality of allogeneic CAR-iNKT cell therapy. Extensive characterization is crucial for clinical translation, but additional research, including preclinical and clinical trials, is essential to determine the safety and effectiveness of CAR19-iNKT cell therapy in real-world applications.
- | ALA-101 / Arovella Therap, testosterone + progesterone (ARG103) / arGentis
Journal: Binding Mechanism of CD47 with SIRP? Variants and Its Antibody: Elucidated by Molecular Dynamics Simulations. (Pubmed Central) - Jul 2, 2023
For B6H12.2, the residues Tyr32, His92, Arg96, Tyr32, Thr52, Ser53, Ala101, and Gly102 in its initial half of the light and heavy chains exhibit obvious energetic and structural impacts upon binding with CD47. The elucidation of the binding mechanism of SIRP?v1, SIRP?v2, and B6H12.2 with CD47 could provide novel perspectives for the development of inhibitors targeting CD47-SIRP?.
- ALA-101 / Arovella Therap
Engineering allogeneic off-the-shelf CD19-directed CAR-iNKT cells without additional genetic manipulations for the treatment of hematological malignancies (Section 37; Poster Board #28) - Mar 14, 2023 - Abstract #AACR2023AACR_2292;
These data demonstrate a unique, off the shelf CAR19-iNKT cell platform for targeting hematological malignancies that combines the specificity of CD19 targeting CAR with the innate features of iNKT cells. The data indicates that iNKT cells are a potent cell type for generating allogeneic off the shelf products for treating a broad spectrum of hematological malignancies and solid tumors by targeting different receptors on the respective tumors.